AtriCure Business Summary

AtriCure, Inc. (ATRC) is a leading medical technology firm that generates revenue through the global sale of proprietary surgical devices for atrial fibrillation (Afib) ablation, left atrial appendage (LAA) management, and post-operative pain relief. The company’s business model is transaction-driven, with revenue segmented into U.S. and International markets and product lines centered on the Isolator Synergy Ablation System, the AtriClip LAA Exclusion System, and the cryoICE/cryoSPHERE platforms. As of February 2026, AtriCure holds a commanding ~60% market share in surgical Afib ablation, with management projecting 2026 revenue of $600 million to $610 million. The company competes directly with Teleflex (TFX), Integra LifeSciences (IART), Artivion, and CardioFocus, maintaining its market leadership through a robust clinical pipeline and the recent launch of its dual-energy PFA/RFA platform. Founded in 2000 by Michael Hooven and Norman Weldon as a spin-off from Enable Medical, AtriCure is currently led by President and CEO Michael H. Carrel, a Wharton MBA who previously served as CEO of Vital Images. The executive leadership team includes CFO Angela L. Wirick, COO Douglas J. Seith, and CTO Salvatore Privitera, JD, who have collectively steered the company toward its first projected year of net income in 2026. The board is chaired by Robert S. White and features high-profile directors such as Shlomi Nachman (ex-Johnson & Johnson) and Maggie S. Yuen (CFO of Penumbra). AtriCure is heavily supported by institutional investors, with over 99% of its equity held by major firms including Vanguard, BlackRock, and PNC Financial Services, reflecting strong market alignment with its transition to positive adjusted EBITDA.